The two big clearance ideas
Peptides are chewed up by proteases and often filtered by kidneys when small. That combination yields short plasma half-lives for many native sequences—great for physiology, hard for once-daily drugs.
Famous enzyme: DPP-4
GLP-1 is rapidly inactivated by dipeptidyl peptidase-4. Analog design blocks that cut site and/or shields the peptide via albumin binding (fatty-acid chains on semaglutide-class molecules).
Engineering toolkit
Cyclization, D-amino acids, N-methylation, PEGylation, lipidation, protein fusion (e.g., Fc), and depot formulations are all strategies to extend exposure. Each trades off potency, immunogenicity, manufacturing cost, or tissue distribution.
Why research powders still ‘work’ in vials
Stability in a lyophilized vial is not the same as half-life in blood. A powder can be stable for months dry and still last minutes in plasma after administration in a living system.
FAQ
Does PEGylation always help?+
It often extends half-life but can reduce receptor potency and complicate manufacturing. It is a design choice, not a universal upgrade.